Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how
Adrian Budhram, Eoin P. Flanagan
Abstract
Testing for myelin oligodendrocyte glycoprotein immunoglobulin G antibodies (MOG-IgG) is essential to the diagnosis of MOG antibody-associated disease (MOGAD). Due to its central role in the evaluation of suspected inflammatory demyelinating disease, the last 5 years has been marked by an abundance of research into MOG-IgG testing ranging from appropriate patient selection, to assay performance, to utility of serum titers as well as cerebrospinal fluid (CSF) testing. In this review, we synthesize current knowledge pertaining to the "who, what, where, when, why, and how" of MOG-IgG testing, with the aim of facilitating accurate MOGAD diagnosis in clinical practice.
Topics & Concepts
Multiple sclerosisMyelin oligodendrocyte glycoproteinMedicineAntibodyImmunologyCerebrospinal fluidOligodendrocyteImmunoglobulin GDiseaseDemyelinating diseaseMyelinPathologyCentral nervous systemInternal medicineExperimental autoimmune encephalomyelitisMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSystemic Lupus Erythematosus Research